Stay updated on AEB1102 Dose Escalation in Advanced Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the AEB1102 Dose Escalation in Advanced Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the AEB1102 Dose Escalation in Advanced Solid Tumors Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:31:24.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update in the dose levels of AEB1102 in patients with advanced cancers in a clinical trial setting.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:34.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for patients, including specific health conditions and prior treatments required for participation. The new criteria specify that patients must have advanced solid tumors and meet certain health benchmarks to be eligible for the trial.
    Difference
    27%
    Check dated 2024-05-22T21:04:09.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:37:18.000Z thumbnail image

Stay in the know with updates to AEB1102 Dose Escalation in Advanced Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the AEB1102 Dose Escalation in Advanced Solid Tumors Clinical Trial page.